BRAF and neoplasm: As described above, several genetic mutations are considered markers of aggressive tumor behavior, including mutations in RAS, PIK3CA, PTEN, P53, ALK, and BRAF genes.6 Once genetic testing is performed, results should be taken into account in determining the treatment plan and to improve treatment outcome.